Bevacizumab experimental — Competitive Intelligence Brief

Bevacizumab experimental (Bevacizumab experimental) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor (monoclonal antibody). Area: Oncology.

phase 3 VEGF inhibitor (monoclonal antibody) VEGF (Vascular Endothelial Growth Factor) Oncology Biologic

Target snapshot

Bevacizumab experimental (Bevacizumab experimental) — Institut de Recherches Internationales Servier. Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis and reducing blood supply to cancer cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bevacizumab experimental TARGET	Bevacizumab experimental	Institut de Recherches Internationales Servier	phase 3	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)
Bevacizumab (Bev)	Bevacizumab (Bev)	Eli Lilly and Company	marketed	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)
Intravitreal bevacizumab	Intravitreal bevacizumab	University of Sao Paulo	marketed	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)
Bevacizumab (Avastin®)	Bevacizumab (Avastin®)	Hanny Al-Samkari, MD	marketed	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)
Intravitreal injection of bevacizumab	Intravitreal injection of bevacizumab	Barnes Retina Institute	marketed	VEGF inhibitor (monoclonal antibody)	VEGF (vascular endothelial growth factor)
Subconjunctival Bevacizumab	Subconjunctival Bevacizumab	Grewal Eye Institute	marketed	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)
Intravitreal Bevacizumab IVB	Intravitreal Bevacizumab IVB	Khyber Teaching Hospital	marketed	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor (monoclonal antibody) class)

1. Institut de Recherches Internationales Servier · 2 drugs in this class
2. Bio-Thera Solutions · 1 drug in this class
3. Centus Biotherapeutics Limited · 1 drug in this class
4. Cipla BioTec Pvt. Ltd. · 1 drug in this class
5. Eli Lilly and Company · 1 drug in this class
6. Grewal Eye Institute · 1 drug in this class
7. Hanny Al-Samkari, MD · 1 drug in this class
8. Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA · 1 drug in this class
9. Khyber Teaching Hospital · 1 drug in this class
10. Mylan Pharmaceuticals Inc · 1 drug in this class